Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS

Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study

(2019) Qian Chen et al.   CLINICAL THERAPEUTICS

Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study

(2018) Chen Wang et al.   LANCET

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

(2018) Alberto Papi et al.   LANCET

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

(2018) David A. Lipson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

(2018) Liwen Fang et al.   Lancet Respiratory Medicine

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

(2018) Brian J Lipworth et al.   International Journal of Chronic Obstructive Pulmonary Disease

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

(2018) Gary T Ferguson et al.   Lancet Respiratory Medicine

Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study

(2017) Gary T. Ferguson et al.   RESPIRATORY MEDICINE

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease

(2017) Nicola A. Hanania et al.   RESPIRATORY MEDICINE

COPD symptom burden: impact on health care resource utilization, and work and activity impairment

(2017) Bo Ding et al.   International Journal of Chronic Obstructive Pulmonary Disease

A Subnational Analysis of Mortality and Prevalence of COPD in China From 1990 to 2013

(2016) Peng Yin et al.   CHEST

Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013

(2016) Maigeng Zhou et al.   LANCET

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

(2016) Dave Singh et al.   LANCET

Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3

(2015) Wendy P. Battisti et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease

(2011) Nanshan Zhong et al.   CURRENT MEDICAL RESEARCH AND OPINION

Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of Adults

(2009) John L. Hankinson et al.   CHEST